

Special Issue

Hepatitis Vaccines: Immunization, Effectiveness and Future Challenges

Message from the Guest Editor

Viral hepatitis, or inflammation of the liver, is caused by a viral infection and remains a major human health problem worldwide. Many different viruses cause viral hepatitis, which includes, in alphabetical order, hepatitis A, B, C, D, and E. WHO's global hepatitis strategy aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030. To reduce the morbidity and mortality, protective vaccination for these hepatitis viruses remains the main goal of public health policy and is a key component of the global viral hepatitis elimination plan. With this aim, in this Special Issue, we will summarize the current knowledge and aim to answer some of the many questions on viral hepatitis, their prevention through vaccination, vaccine effectiveness, and future challenges in this field. We invite the submission of original research and review articles that cover any aspect of viral hepatitis, prevention through vaccines, prophylactic and therapeutic vaccines, vaccine development and technology, vaccine immunity, etc.

Guest Editor

Dr. Muhammad Atif Zahoor

Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

Deadline for manuscript submissions

closed (30 September 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/189962

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).